UY33794A - Inhibidores diméricos de las iap - Google Patents

Inhibidores diméricos de las iap

Info

Publication number
UY33794A
UY33794A UY0001033794A UY33794A UY33794A UY 33794 A UY33794 A UY 33794A UY 0001033794 A UY0001033794 A UY 0001033794A UY 33794 A UY33794 A UY 33794A UY 33794 A UY33794 A UY 33794A
Authority
UY
Uruguay
Prior art keywords
iap
dimeric
dimeric inhibitors
formula
inhibitors
Prior art date
Application number
UY0001033794A
Other languages
English (en)
Inventor
Christopher Sean Straub
Chen Zhuoliang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY33794A publication Critical patent/UY33794A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

El presente invento proporciona compuestos de la fórmula M- L- M' (donde M y M' son cada uno, de manera independiente, una fracción monomérica de la fórmula (I) y L es un enlazador). Se ha encontrado que los compuestos diméricos son efectivos para promover la apoptosis en células que se estén dividiendo rápidamente.
UY0001033794A 2010-12-13 2011-12-09 Inhibidores diméricos de las iap UY33794A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42242210P 2010-12-13 2010-12-13

Publications (1)

Publication Number Publication Date
UY33794A true UY33794A (es) 2012-07-31

Family

ID=45349201

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033794A UY33794A (es) 2010-12-13 2011-12-09 Inhibidores diméricos de las iap

Country Status (8)

Country Link
US (1) US8993523B2 (es)
EP (1) EP2651919A1 (es)
JP (1) JP2013545781A (es)
CN (1) CN103347874B (es)
AR (1) AR084251A1 (es)
TW (1) TW201307318A (es)
UY (1) UY33794A (es)
WO (1) WO2012080271A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2015092420A1 (en) * 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
CN108610333B (zh) * 2018-06-08 2020-04-03 绍兴文理学院 诱导MDM2自我降解E3泛素连接酶二聚体酰胺类小分子PROTACs
CN112533898A (zh) * 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN114163438A (zh) * 2021-12-13 2022-03-11 无锡捷化医药科技有限公司 一种2-甲基-3-羰基吡唑并[4,3-c]吡啶-7-羧酸盐酸盐的制备方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
ATE415413T1 (de) 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
ATE481092T1 (de) 2002-11-27 2010-10-15 Irm Llc Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20110251134A1 (en) 2004-02-05 2011-10-13 Leigh Zawel Combination of (a) a dna toposomerase inhibitor and (b) an iap inhibitor
CA2582734C (en) 2004-03-01 2011-05-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
MX2007010371A (es) 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
US20110183358A1 (en) 2005-03-17 2011-07-28 The Burnham Institute Methods and compositions for derepression of iap-inhibited caspase
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20100256046A1 (en) 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007021825A2 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20070203749A1 (en) 2005-08-09 2007-08-30 Sri Chunduru Business methods for compounds for treatment of proliferative disorders
BRPI0617751A2 (pt) 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
ES2684120T3 (es) 2005-12-20 2018-10-01 Novartis Ag Combinación de un inhibidor de IAP y un taxano
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
WO2007136921A2 (en) 2006-03-21 2007-11-29 Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049563B1 (en) 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014252A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CN101595121A (zh) * 2006-10-12 2009-12-02 诺瓦提斯公司 作为iap抑制剂的吡咯烷衍生物
EP2076778A2 (en) 2006-10-19 2009-07-08 Novartis AG Organic compounds
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
WO2008085610A1 (en) 2006-11-28 2008-07-17 Novartis Ag Use of iap inhibitors for the treatment of acute myeloid leukemia
WO2008109057A1 (en) 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Organic compounds and their uses
AU2008240153B2 (en) 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
NZ580226A (en) 2007-04-30 2012-11-30 Genentech Inc Dimer compounds as inhibitors of iap
US20110008802A1 (en) 2007-05-07 2011-01-13 Tetralogic Pharmaceuticals Corp. TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
US20100203012A1 (en) 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
PE20140100A1 (es) 2007-09-12 2014-02-12 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
MX2010007543A (es) 2008-01-11 2010-09-30 Genentech Inc Inhibidores de iap.
AU2009206588A1 (en) 2008-01-24 2009-07-30 Tetralogic Pharmaceuticals Corporation IAP inhibitors
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CA2728933A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009282978A1 (en) 2008-08-16 2010-02-25 Genentech, Inc. Azaindole inhibitors of IAP
WO2010033531A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
WO2010031171A1 (en) 2008-09-19 2010-03-25 Aegera Therapeutics, Inc. Iap bir domain binding compounds
CA2737280A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
EP2434890A4 (en) 2009-05-28 2013-01-02 Tetralogic Pharm Corp IAP INHIBITORS
CA2763614A1 (en) 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011016576A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Alanine derivatives as inhibitors of apoptosis proteins
US8815927B2 (en) 2009-10-23 2014-08-26 The Regents Of The University Of Michigan Bivalent diazo bicyclic Smac mimetics and the uses thereof
CN102050867A (zh) 2009-11-10 2011-05-11 上海艾力斯医药科技有限公司 四肽类似物、制备方法及其应用
WO2011068926A1 (en) 2009-12-04 2011-06-09 Tetralogic Pharmaceuticals Corp. Iap inhibitors
KR101230851B1 (ko) 2010-01-19 2013-02-07 한미사이언스 주식회사 세포사멸 유도 활성을 갖는 이미다조피라진온 유도체
CN102985439B9 (zh) 2010-02-12 2016-08-03 制药科学股份有限公司 Iap bir结构域结合化合物
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
CN103261186A (zh) 2010-12-13 2013-08-21 诺瓦提斯公司 二聚化iap抑制剂

Also Published As

Publication number Publication date
TW201307318A (zh) 2013-02-16
CN103347874A (zh) 2013-10-09
US20130309247A1 (en) 2013-11-21
US8993523B2 (en) 2015-03-31
CN103347874B (zh) 2014-10-29
EP2651919A1 (en) 2013-10-23
AR084251A1 (es) 2013-05-02
JP2013545781A (ja) 2013-12-26
WO2012080271A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
UY33794A (es) Inhibidores diméricos de las iap
UY33236A (es) Inhibidores dimericos de las iap
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
ECSP13013074A (es) Nuevos derivados de piridina
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20140464A (es) Compuestos de heterociclilo
CR20150250A (es) Nuevos derivados de piridina
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CU20140025A7 (es) Pirimidinas anilladas sustituidas
UY34333A (es) ?métodos y composiciones para el control de malezas, y métodos para reducir la expresión de enzima dhps?
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
CR20150204A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20150447A (es) Nuevos derivados de pirazol
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CO6741154A2 (es) Compuestos de triazolopiridina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
TR201908180T4 (tr) N1-asil- 5-floropirimidinon deriveleri.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200217

109 Application deemed to be withdrawn

Effective date: 20210618